COMP <GO>
IBRX vs MRK // FORWARD P/E MULTIPLE
ImmunityBio Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: IBRX 3
— MRK 11
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
forward-pe
29.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 20.70% | -48.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 3.42% | -6.75 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.19 | -4.74 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 56.9 | -13.05 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.92 | +0.13 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 29.0x | 18.4x | +10.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $361.02B | -$351.76B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | MRK REV | IBRX GROSS % | MRK GROSS % | IBRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $65.01B | 99.3% | 74.8% | -$308.8M | $12.36B |
| FY 2024 | $14.7M | $64.17B | 100.0% | 76.3% | -$398.1M | $18.10B |
| FY 2023 | $622.0K | $60.12B | 44.0% | 44.0% | -$366.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
MRK // BETA 0.92